PYPDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PolyPid Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 25, 2026
$4.88+0.16 (+3.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 2.3
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| EPS, diluted | -57.4% | -67.5% | -56.5% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 496.4% | -366.3% | |
| Return on assets | – | -67.3% | -143.8% | |
| Current ratio | – | 16.41 | 1.97 | |
| Debt to equity | – | – | – | |
| Diluted shares | – | 0M | 16M |
Where the cash went
Fiscal 2021 to 2025, five years combined
PolyPid generated $133.78M from operations and spent $4.90M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$133.78M
Used
$4.90M
Capital expenditure$4.90M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$34.17M
- Cash generatingOperating cash flow above zero-$27.88M
- Return on assets improvedROA up on the prior year-188.8% → -135.5%
- Earnings backed by cashOperating cash flow above net income-$27.88M vs -$34.17M
- Less leverageLong-term debt to assets fell2.5% → –
- Better liquidityCurrent ratio rose1.31 → 1.97
- No dilutionShare count did not rise6M → 16M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –